Personal information

Activities

Collapse all

Works (4)

Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial.

Frontiers in oncology
2024-03-07 | Journal article
DOI: 10.3389/fonc.2024.1179232
PMID: 38515570
PMC: PMC10955356
Contributors: Dong W; Yin Y; Liu B; Jiang Y; Wang L; Shi D; Qin J
Source: Self-asserted source
Jianwen Qin

Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.

BMC cancer
2024-01-30 | Journal article
DOI: 10.1186/s12885-024-11902-w
PMID: 38291354
PMC: PMC10829328
Contributors: Dong W; Yin Y; Yang S; Liu B; Chen X; Wang L; Su Y; Jiang Y; Shi D; Sun D et al.
Source: Self-asserted source
Jianwen Qin

Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.

Clinical lung cancer
2023-11-02 | Journal article
DOI: 10.1016/j.cllc.2023.10.009
PMID: 38008641
Contributors: Chen Q; Wang J; Wang X; Yin Y; Wang X; Song Z; Xing B; Li Y; Zhang J; Qin J et al.
Source: Self-asserted source
Jianwen Qin
grade
Preferred source (of 2)‎

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.

Frontiers in oncology
2023-11-01 | Journal article
DOI: 10.3389/fonc.2023.1227980
PMID: 38023218
PMC: PMC10646488
Contributors: Chen Q; Zhang J; Wang X; Zong W; Sun L; Qin J; Yin Y
Source: Self-asserted source
Jianwen Qin
How many people are using ORCID?